Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,532.00+3.57%ETH$2,430.70+6.20%GOLD$4,072.20+3.34%OIL$88.04-8.38%
Smart Investors Daily
SID Premium
CR

NASDAQ · CRBU

Caribou Biosciences, Inc.

Healthcare · Biotechnology

$0.46

Down-$0.02 (-3.27%)

Updated Nov 4, 2026, 10:07 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
173.35M
P/E ratio
-1.11
Dividend yield
0.00%
52-week range
$0.41 – $2.49
Volume
1.39M
Avg. volume
2.34M

Price performance · CRBU

CRBU price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

CRBU closed at $0.46 after 21 trading sessions, down 59.52% for the selected period.

Last close
$0.46
Period change
-59.52%
Period low
$0.42
Period high
$1.14
Daily close
View OHLC price history
CRBU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.427$0.465$0.415$0.45941.39M
Nov 2, 2026$0.4346$0.4498$0.41$0.43993.3M
Oct 30, 2026$0.445$0.4453$0.4135$0.42322.31M
Oct 29, 2026$0.4871$0.4995$0.4448$0.4452.84M
Oct 28, 2026$0.4687$0.4915$0.4607$0.48941.06M
Oct 27, 2026$0.4872$0.4948$0.4553$0.46072.37M
Oct 26, 2026$0.5328$0.5359$0.4909$0.49221.93M
Oct 23, 2026$0.5499$0.5768$0.5328$0.53282.16M
Oct 22, 2026$0.528$0.5641$0.5207$0.562.78M
Oct 21, 2026$0.5199$0.55$0.5116$0.54442.26M
Oct 20, 2026$0.4694$0.5254$0.4625$0.5193.41M
Oct 19, 2026$0.4644$0.478$0.4594$0.4643.8M
Oct 16, 2026$0.47$0.4781$0.4491$0.46992.95M
Oct 15, 2026$0.46$0.4767$0.4465$0.46472.88M
Oct 14, 2026$0.4772$0.4842$0.4448$0.46013.71M
Oct 13, 2026$0.482$0.495$0.45$0.474.55M
Oct 12, 2026$0.452$0.5069$0.4449$0.49695.26M
Oct 9, 2026$0.46$0.5194$0.4425$0.46029.74M
Oct 8, 2026$0.5938$0.5968$0.4503$0.481219.34M
Oct 7, 2026$0.636$0.67$0.546$0.617437.51M
Oct 6, 2026$1.19$1.215$1.13$1.1355.94M

Latest CRBU news

The latest Smart Investors Daily articles mentioning CRBU.

Stock researchCompany · Overview

CRBU research

Overview

Company profile and research snapshot.

Company profile

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
CRBU recent ratings
DateFirmRatingTarget
Oct 8, 2026HC Wainwright & Co.Neutral—
Oct 7, 2026Brookline CapitalHold—
Oct 7, 2026RBC CapitalSector Perform—
Oct 7, 2026Leerink PartnersMarket Perform—
Aug 14, 2026B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Caribou Biosciences (CRBU) Stock Fair Value Falls After Clinical Programs Are Halted

Caribou Biosciences is back in focus after fair value estimates shifted from about US$11.86 to US$5.75 per share, echoing recent price target resets across Wall Street coverage. Analysts are reacting to halted clinical programs, discontinued CAR-T efforts, and an active review of strategic options. Taken together, these developments frame a very different story than when prior US$5 to US$6 targets were in place. As you read on, you will see how these revisions shape the evolving analyst...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By